New Once-Yearly Osteoporosis Treatment For Preventing Fractures And Bone Loss!

Anyone can develop osteoporosis, but it is common in older women.

Osteoporosis makes your bones weak and they are more likely to break.

It affects both men and women. Women are affected with osteoporosis because of less bone mass than men.

Women after menopause need estrogen hormone to keep their bones strong, but after menopause estrogen levels fall.

As ovaries also make estrogen, if they are removed by surgery, fast bone loss may occur. Therefore, bone loss speeds up in women after menopause.

Hormone replacement therapy (HRT) is one way to prevent bone loss in women. HRT replaces the estrogen that is declined due to menopause. Women who take HRT are at an increased risk of heart attack, Alzheimer’s, breast cancer, stroke and blood clots.

The reason for the development of osteoporosis in men is high levels of stress in daily lives that leads to sex hormone reduction produced by men, which significantly leads to osteoporosis. Men are producing high levels of stress hormones, such as prolactin and cortozol, which leads to reduction in testosterone levels.

Risk of osteoporosis with prostate cancer treatment:

Prostate cancer is likely to increase the risk of fractures up to eight times. According to recent study, androgen deprivation therapy roughly doubles the risk of fractures in prostate cancer patients. Hormones such as testosterone protect against bone loss.

Suppressing testosterone and other androgen hormones helps in controlling the growth and spread of prostate tumors. Once, these hormones are blocked, bone becomes less dense and breaks more easily, which means osteoporosis is a common side effect of the therapy.

Therefore, adequate calcium levels are important to prevent the risk. Men, who are taking prostate cancer treatment, should take at least 1000 milligrams of calcium daily. Vitamin D and quitting smoking are also important in osteoporosis treatment.

Risk of osteoporosis reduces with new once-yearly treatment:

Novartis has launched the zoledronic acid 5 milligram solution for infusion, which is a first and once-yearly treatment for osteoporosis approved by FDA (Food and Drug Administration). This drug is a breakthrough for postmenopausal osteoporosis treatment as it strengthens bones and protects fractures with a single once-yearly dose.

Zoledronic acid drug belongs to a class of biphosphonates drugs, which are used for postmenopausal osteoporosis treatment. This drug is given once a year by infusion. A single infusion is useful for patient in protecting the complications of bone loss for full year.

The procedure is done at infusion centers and can be completed within 15 minutes. Patient can relax, listen to music or watch television during the procedure. Afterwards, the patient can return to his/her normal duties.